Business Wire

MA-LINEDATA

Share
Linedata Launches First Integrated ESG Data Solution for Asset Managers with Market Leader Arabesque S-Ray

Linedata, a global provider of credit and asset management technology, data and services, today announced it is the first technology vendor to seamlessly integrate Environmental, Social, and Governance (ESG) data into asset managers’ workflows through collaboration with leading independent provider Arabesque S-Ray . A wide range of ESG data assets feeds directly into Linedata’s software to help managers meet growing demands from regulators and investors for greater transparency over ESG funds, and to provide a competitive edge through sustainable positioning and differentiated product offerings.

Arabesque S-Ray’s quantitative data tool uses machine learning to crunch the sustainability performance of over 8,000 of the world’s largest listed companies, and directly integrates with Linedata’s portfolio and order management solutions for unparalleled ease of use. It is available to Linedata clients in Europe, Asia, and North America.

“We believe economic value creation can go hand in hand with environmental stewardship, social inclusion, and sound governance,” noted Georg Kell, Chairman of the Arabesque Group, and founding Executive Director of the United Nations Global Compact. “Our agreement with Linedata empowers more asset managers to make better decisions for a sustainable future.”

Positioning powerful ESG intelligence at the fingertips of Linedata’s over 450 global asset management clients helps managers support ESG decision-making and adapt to evolving requirements under Europe’s new Sustainable Finance Disclosure Regulation (SFDR) and the United States’ new ESG agenda.

The move also marks an expansion of Linedata’s Data Management Service, a key component of its cloud-based Asset Management Platform - AMP launched last year. It offers an innovative commercial model which gives basic ESG and UN Global Compact scores to users of Linedata software, and the flexibility to access premium data on a usage basis, a break from the industry standard.

“Linedata is committed to helping market participants to make more and better ESG driven decisions. With sustainable fund assets hitting a record $1.7 trillion in 20201 , asset managers recognize ethical and sustainable funds as a major growth opportunity,” said Gary Brackenridge, Linedata’s Global Head of Asset Management. “The combination of Arabesque’s market-leading ESG data seamlessly integrated into Linedata’s cloud-based portfolio workflows with a unique usage model fits with what we know clients are looking for: commercial flexibility, high-value content and excellent user experience.”

Providing instant access to Arabesque S-Ray’s data supports the wider industry shift to ESG investing, while removing a major operational burden from asset managers. The ability to leverage independently validated ESG scores streamlines and accelerates the development of ethical, sustainable and funds and in turn helps guide which companies consciously minded investors and consumers choose to support.

Users benefit from ESG data insights throughout the entirety of their investment operations:

  • Score, rebalance, and create new ESG portfolio strategies, products, and workflows
  • Integrate ESG factors into pre- and post-trade Compliance at asset and fund level
  • Manage regulatory and investor transparency and reporting with dashboards, screening, and monitoring tools

To learn more about Linedata’s Data Management Service - ESG Inside, visit linedata.com/ESG

Linedata is pleased to have won Best Data Management Solution at Hedgeweek European Awards 2021 at a virtual gala on Thursday March 11, 2021.

1 Sustainable investment indexes outperform and protect on the downside: Morningstar , 16.02.21

ABOUT ARABESQUE S-RAY

S-Ray® is an AI-based tool developed by Arabesque that analyses the sustainability performance of approximately 8,000 of the world’s largest listed corporations using self-learning quantitative models and data scores. The technology systematically combines over 200 ESG metrics with news signals from over 30,000 sources across 170 countries. It is the first tool of its kind to rate companies on the normative principles of the United Nations Global Compact (GC Score). Additionally, S-Ray provides an industry-specific assessment of companies’ performance on financially material sustainability criteria (ESG Score). Both scores are combined with a preferences filter that assesses a company’s business involvements. S-Ray daily data products and services are used by some of the world’s leading financial institutions, investors, corporations, and consultants.

www.arabesque.com/s-ray

ABOUT LINEDATA

With 20 years’ experience and 700 clients in 50 countries, Linedata’s 1100 employees in 20 offices provide global humanized technology solutions and services for the asset management and credit industries that help its clients to evolve and to operate at the highest levels.

Headquartered in France, Linedata achieved revenues of EUR 161.0 million in 2020 and is listed on Euronext Paris compartment B FR0004156297-LIN – Reuters LDSV.PA – Bloomberg LIN:FP.

linedata.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye